← Back to Search

Radiopharmaceutical

Targeted Radiotherapy for Brain Tumor

Phase 1
Recruiting
Research Sponsored by Cellectar Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed throughout the study to 1-year post-infusion follow-up period
Awards & highlights

Study Summary

This trial tests higher doses of a new drug to see if it is safe and effective for treating kids, teens, and young adults with HGG.

Who is the study for?
This trial is for children, adolescents, and young adults aged 2-25 with high-grade glioma (a type of brain tumor) that has come back or hasn't responded to treatment. They must be in a stable condition, not pregnant, able to follow the study plan, and have certain blood counts and organ functions within specific ranges.Check my eligibility
What is being tested?
The trial is testing two different doses of CLR 131 to see how safe it is and if it works against relapsed or refractory high-grade gliomas in pediatric patients. It's a dose-finding study which means they're trying to find the right amount of drug that's effective but also safe.See study design
What are the potential side effects?
While the exact side effects are not listed here, similar targeted radiotherapies can cause nausea, fatigue, loss of appetite, hair loss at the site of treatment. There may also be risks associated with radiation exposure such as damage to healthy tissue.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed throughout the study to 1-year post-infusion follow-up period
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed throughout the study to 1-year post-infusion follow-up period for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy Evaluation for Progression Free Survival
Safety Evaluation of CLR 131
Secondary outcome measures
Dose Determination for CLR 131
Dosimetry Evaluation for Total Body and Organ
Treatment Response of CLR 131
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pediatric High-Grade Glioma PatientsExperimental Treatment1 Intervention
Two dosing cohorts will be explored; patients in the first arm will receive two doses, 20 mCi/m2 each, separated by 14 days for two cycles, with a third optional cycle. Patients in the second arm will receive two doses, 10 mCi/m2 each, separated by 14 days for three cycles with a fourth optional cycle.

Find a Location

Who is running the clinical trial?

Cellectar Biosciences, Inc.Lead Sponsor
14 Previous Clinical Trials
1,215 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,672 Previous Clinical Trials
40,926,391 Total Patients Enrolled
Jarrod LongcorStudy DirectorChief Operating Officer
2 Previous Clinical Trials
150 Total Patients Enrolled

Media Library

CLR 131 (Radiopharmaceutical) Clinical Trial Eligibility Overview. Trial Name: NCT05610891 — Phase 1
Brain Tumor Research Study Groups: Pediatric High-Grade Glioma Patients
Brain Tumor Clinical Trial 2023: CLR 131 Highlights & Side Effects. Trial Name: NCT05610891 — Phase 1
CLR 131 (Radiopharmaceutical) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05610891 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How hazardous is it for individuals to be afflicted with Pediatric High-Grade Glioma?

"As this is an early-stage trial, the safety of Pediatric High-Grade Glioma Patients was rated 1 due to limited evidence currently available."

Answered by AI

What aims are this study hoping to accomplish?

"The central objective of this clinical trial is to appraise Progression Free Survival through a 1-year post-infusion follow up period and 3 years following completion of treatment. Other secondary goals include assessing the therapeutic efficacy (through reduction in tumor volume) and dosage level, as well as determining how CLR 131 impacts tumour response when assessed with SPECT/CT imaging modalities."

Answered by AI

Could I potentially qualify for inclusion in this experiment?

"To be considered for this research endeavour, patients must have glioma and fall within the 2 to 25 year old age range. This clinical trial is looking for 50 individuals in total."

Answered by AI

Are there any remaining openings to partake in this research?

"According to the data on clinicaltrials.gov, this study is no longer open for patient recruitment. Originally posted in November 1st 2022 and last updated 3 days later, 358 other trials are still actively searching for subjects at present."

Answered by AI

Are individuals over the age of 45 eligible for participation in this medical experiment?

"This clinical trial is looking for participants ranging in age from 2 to 25 years."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
2023. "Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05610891.
~33 spots leftby May 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top